ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
Sponsor
Novartis Pharmaceuticals (Industry)
Overall Status
Completed
CT.gov ID
NCT00466063
Collaborator
(none)
108
23
98
4.7
0
Study Details
Study Description
Brief Summary
This registry will evaluate long-term safety and efficacy of deferasirox in children with transfusional iron overload.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Study Design
Study Type:
Observational
Actual Enrollment
:
108 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Study Start Date
:
May 1, 2007
Actual Primary Completion Date
:
Jul 1, 2015
Actual Study Completion Date
:
Jul 1, 2015
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
ICL670 ICL670 |
Drug: Deferasirox
|
Outcome Measures
Primary Outcome Measures
- Safety - renal and hepatic function monitoring. [5 years]
Secondary Outcome Measures
- Adverse events [5 years]
- Longitudinal ferritin levels [5 years]
- Assessment of auditory and ophthalmologic status [5 years]
Eligibility Criteria
Criteria
Ages Eligible for Study:
2 Years
to 5 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
History of transfusion-dependent anemia.
-
History of iron overload
Exclusion Criteria:
- Patients with non-transfusional hemosiderosis.
Other protocol-defined inclusion/exclusion criteria may apply.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University of South Alabama Medical Center | Mobile | Alabama | United States | 36604 |
2 | Children's Hospital Los Angeles | Los Angeles | California | United States | 90027 |
3 | Children's Hospital Oakland | Oakland | California | United States | 94609 |
4 | Children's Hospital of Orange County | Orange | California | United States | 92868-3874 |
5 | Stanford University Medical Center | Stanford | California | United States | 94304 |
6 | MD Anderson Cancer Center - Orlando | Orlando | Florida | United States | 32806 |
7 | St. Joseph's Children's Hospital of Tampa | Tampa | Florida | United States | 33609 |
8 | Children's Memorial Hospital | Chicago | Illinois | United States | 60614-3394 |
9 | Children's Hospital Boston | Boston | Massachusetts | United States | 02115 |
10 | Hackensack University Medical Center | Hackensack | New Jersey | United States | 07601 |
11 | St. Joseph's Children's Hospital | Paterson | New Jersey | United States | 07503 |
12 | The Brooklyn Hospital Center | Brooklyn | New York | United States | 11201 |
13 | Schneider Children's Hospital | New York | New York | United States | 11040 |
14 | SUNY - Upstate Medical University | Syracuse | New York | United States | 13210 |
15 | East Carolina University | Greenville | North Carolina | United States | 27858 |
16 | Akron Children's Hospital | Akron | Ohio | United States | 44308-1062 |
17 | Children's Medical Center | Dayton | Ohio | United States | 45404 |
18 | Oklahoma State University Health Sciences Center | Oklahoma City | Oklahoma | United States | 73104 |
19 | Penn State University / Milton S. Hershey Medical Center | Hershey | Pennsylvania | United States | 17033-0850 |
20 | St. Jude Children's Research Hospital Memphis | Memphis | Tennessee | United States | 38105-2794 |
21 | Cook's Children's Medical Center | Fort Worth | Texas | United States | 76104 |
22 | Texas Children's Hospital | Houston | Texas | United States | 77030 |
23 | Children's Hospital of the King's Daughters | Norfolk | Virginia | United States | 23507 |
Sponsors and Collaborators
- Novartis Pharmaceuticals
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Novartis Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00466063
Other Study ID Numbers:
- CICL670A2411
First Posted:
Apr 27, 2007
Last Update Posted:
Dec 29, 2015
Last Verified:
Dec 1, 2015
Keywords provided by Novartis Pharmaceuticals
Additional relevant MeSH terms: